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Initially described by Jaeken et al. in 1980, congenital dis-
orders of glycosylation (CDG) is a rapidly expanding
group of human multisystemic disorders. To date, many
CDG patients have been identiﬁed with deﬁciencies in the
conserved oligomeric Golgi (COG) complex which is a
complex involved in the vesicular intra-Golgi retrograde
trafﬁcking. Composed of eight subunits that are organized
in two lobes, COG subunit deﬁciencies have been associ-
ated with Golgi glycosylation abnormalities. Analysis of
the total serum N-glycans of COG-deﬁcient CDG patients
demonstrated an overall decrease in terminal sialylation
and galactosylation. According to the mutated COG sub-
units, differences in late Golgi glycosylation were observed
and led us to address the question of an independent role
and requirement for each of the two lobes of the COG
complex in the stability and localization of late terminal
Golgi glycosylation enzymes. For this, we used a small-
interfering RNAs strategy in HeLa cells stably expressing
green ﬂuorescent protein (GFP)-tagged β1,4-galactosyl-
transferase 1 (B4GALT1) and α2,6-sialyltransferase 1
(ST6GAL1), two major Golgi glycosyltransferases
involved in late Golgi N-glycosylation. Using ﬂuorescent
lectins and ﬂow cytometry analysis, we clearly demon-
strated that depletion of both lobes was associated with
deﬁciencies in terminal Golgi N-glycosylation. Lobe A
depletion resulted in dramatic changes in the Golgi struc-
ture, whereas lobe B depletion severely altered the stability
of B4GALT1 and ST6GAL1. Only MG132 was able to
rescue their steady-state levels, suggesting that B4GALT1-
and ST6GAL1-induced degradation are likely the conse-
quence of an accumulation in the endoplasmic reticulum
(ER), followed by a retrotranslocation into the cytosol and
proteasomal degradation. All together, our results suggest
differential effects of lobe A and lobe B for the localiz-
ation/stability of B4GALT1 and ST6GAL1. Lobe B would
be crucial in preventing these two Golgi glycosyltrans-
ferases from inappropriate retrograde trafﬁcking to the
ER, whereas lobe A appears to be essential for maintain-
ing the overall Golgi structure.
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Introduction
The endoplasmic reticulum (ER) and Golgi apparatus are key
organelles in the secretory pathway of proteins and lipids.
Among the post-translational modiﬁcations occurring in these
distinct compartments, one of the most important is the glyco-
sylation consisting in the covalent attachment of glycans to
proteins (Van den Steen et al. 1998; Ferrari et al. 2001;
Helenius and Aebi 2004). N-Glycosylation ﬁrst takes place in
the ER lumen with the assembly of a dolichol-linked oligo-
saccharide, later transferred from its lipid carrier to nascent
proteins. Within the ER but especially in the Golgi apparatus,
a complete remodeling of the glycan structure is achieved by
the subsequent action of glycosyltransferases and glycosidases
resulting in a mature complex type N-glycan (Kornfeld R and
Kornfeld S 1985). A correct glycan structure, crucial for
many cellular biological functions, not only depends on the
activity of glycosylation enzymes, but also requires their
speciﬁc localization within the Golgi cisternae (see Foulquier
2009 for review).
The molecular mechanisms by which this distribution
within the different Golgi stacks is established and maintained
are still obscure but seem to be based on a dynamic process,
achieved by a ﬁnely regulated balance between anterograde
and retrograde trafﬁcking (Fotso et al. 2005). Different
models have been proposed regarding the vesicular Golgi traf-
ﬁcking. For several years, the main models were the vesicular
transport and the cisternal maturation models (Pelham and
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Rothman 2000; Elsner et al. 2003, review). Recently, a third
model was however proposed by Patterson et al. (2008). This
model postulates that the mammalian Golgi apparatus presents
a two-dimensional gradient in lipid composition, governing
the steady-state distribution of transmembrane cargo proteins
and glycosylation enzymes.
Independent of the speciﬁc model, the precise distribution
of the glycosyltransferases within the Golgi apparatus requires
a complex transport machinery. Part of the machinery consists
of the conserved oligomeric Golgi (COG) complex Ungar
et al. (2002), a peripheral Golgi octa heteromeric complex
composed of eight subunits (Cog1–8) arranged in two distinct
lobes: lobe A (Cog1–4) and lobe B (Cog5–8) whose cellular
roles have not yet been fully elucidated. Several studies high-
lighted its functions in trafﬁcking and/or stability of Golgi
glycosylation enzymes. Indeed, a set of seven COG sensitive,
type II integral membrane proteins called GEARs presented
decreased steady-state levels in ldlB and ldlC Chinese
hamster ovary (CHO) cell lines, which are deﬁcient in Cog1
and Cog2, respectively (Oka et al. 2004). These proteins have
been found to accumulate in “COG complex-dependent”
(CCD) vesicles in small-interfering RNA (siRNA)-induced
Cog3-depleted cells (Zolov and Lupashin 2005). Further
analysis also suggested that the COG complex regulated the
efﬁcient vesicle tethering of Golgi enzymes by a constant
retrieval to their correct localization in CCD vesicles
(Shestakova et al. 2006). The COG complex might act as a
tethering factor, mediating an interaction between an
ER-derived vesicle and its Golgi target via SNARE-mediated
fusion (see Ungar et al. 2006 for review). The critical require-
ment of COG proteins for Golgi glycosylation has been
demonstrated by the identiﬁcation of several COG-deﬁcient
congenital disorders of glycosylation (CDG) patients. Initially
described by Jaeken et al. (1980), two types of CDGs were
deﬁned according to the cellular localization of the deﬁciency:
type I CDGs caused by alterations in the assembly or transfer
of the dolichol-linked oligosaccharide precursor and type II
CDGs involving defects in the processing of protein bound
N-linked oligosaccharides within the ER and/or Golgi. The
ﬁrst CDG case linked to COG subunit deﬁciency was docu-
mented by Wu et al. (2004). Up to date, patients presenting
mutations in Cog1 and Cog4–8 subunits have been identiﬁed
(Wu et al. 2004; Spaapen et al. 2005; Foulquier et al. 2006;
Steet and Kornfeld 2006; Foulquier et al. 2007; Kranz et al.
2007; Ng et al. 2007; Paesold-Burda et al. 2009; Reynders
et al. 2009; Lübbehusen et al. 2010). According to the mass
spectrometry analysis of total serum, we have shown that both
N- and O-glycosylation were impaired in COG-deﬁcient CDG
patients (Reynders et al. 2009). Indeed, an overall decrease in
both sialylation and galactosylation and strong differences in
the relative amounts and the presence of unexpected oligosac-
charide structures were observed in all COG-deﬁcient CDG
patients tested so far. In ﬁbroblasts derived from patients,
mutations of some COG subunits resulted in signiﬁcantly
reduced activities of nucleotide-sugar transporters and a
decreased stability of some Golgi enzymes such as Golgi
mannosidase II and β1,4-galactosyltransferase 1 (B4GALT1;
Foulquier et al. 2006, 2007; Kranz et al. 2007). Depending on
the various COG-deﬁcient patient cells, differences mostly
affecting the late Golgi glycosylation were observed. These
differences that are likely to result from the severity of the
mutation within the given subunits led us to address the ques-
tion of an independent role and requirement for each of the
two lobes of the COG complex in the stability and/or the
localization of late terminal Golgi glycosylation enzymes.
Given that two main Golgi glycosyltransferases are involved
in the late Golgi N-glycosylation reaction: the β1,4-galactosyl-
transferase 1 (B4GALT1) and the α2,6-sialyltransferase 1
(ST6GAL1), a strategy with siRNAs to knockdown the
expression of Cog3p and Cog7p for the lobe A and lobe B,
respectively was used in HeLa cells stably expressing either
green ﬂuorescent protein (GFP)-tagged B4GALT1
(GalT1-GFP) or GFP-tagged ST6GAL1 (SiaT1-GFP).
We demonstrated that Cog3p depletion, while accompanied
by an extensive Golgi fragmentation, had no effects on the
steady-state levels of B4GALT1 and ST6GAL1. Strikingly
and at the opposite, we could show that Cog7 depletion
severely altered the steady-state levels of both enzymes. A
quantitative polymerase chain reaction (QPCR) approach
allowed us to exclude any transcriptional regulation of
B4GALT1 and ST6GAL1 in response to siRNA-mediated dis-
ruption of the lobe B of the COG complex. Furthermore, we
used different lysosomal and proteasomal inhibitors to assess
the stability of both enzymes under siCog7. Interestingly, only
treatment with MG132 was able to rescue the steady-state
level of both B4GALT1 and ST6GAL1 following Cog7p
depletion. Therefore, we concluded that lobe B of the COG
complex is crucial for the stability of these two enzymes.
Interestingly, both Cog3p and Cog7p depletion were corre-
lated with deﬁciencies in the terminal N-glycosylation as esti-
mated by ﬂow cytometry analysis with FITC-labeled lectins.
Moreover, we showed that the disruption of either lobe A or
lobe B of the COG complex can also affect different subsets
of secretory-pathway-related proteins. Our data then suggest
the existence of functional COG subcomplexes with indepen-
dent and functional lobes that inﬂuence the Golgi
N-glycosylation independently. Lobe A is involved in main-
taining the structural Golgi organization, whereas lobe B has
a key role in B4GALT1 and ST6GAL1 stability.
Results
Steady-state level and intracellular distribution of B4GALT1
and ST6GAL1 in siCog3- and siCog7-transfected cells
To investigate the effects of either lobe A or lobe B of the
COG complex on the Golgi localization and the steady-state
level of both B4GALT1 and ST6GAL1, siRNA duplexes
against Cog3p and Cog7p were designed to speciﬁcally
mediate either lobe A or lobe B knockdowns of the COG
complex. HeLa cells stably expressing either GalT1-GFP or
SiaT1-GFP were shown to colocalize speciﬁcally with the
cis-Golgi marker GM130 as indicated by the predominant
yellow staining in the perinuclear region (Figure 1A and B,
control). As shown in Figure 2, treatment of HeLa cells with
siCog3 or Cog7 resulted in a substantial knockdown of their
respective protein level by immunoblotting corresponding to a
loss of 85–90% compared with untreated cells (Figure 2A). As
published previously, we observed that Cog3p depletion was
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Fig. 1. Respective effects of siRNA induced COG3 KD (siCog3) and COG7 KD (siCog7) on Golgi morphology, steady-state levels and subcellular localization
of B4GALT1 and ST6GAL1. HeLa cells stably expressing GalT1-GFP (A) and SiaT1-GFP (B) were transfected with either siCog3 or siCog7 at a concentration
of 200 nM in the absence of fetal bovine serum. After 96 h, cells were ﬁxed, stained with DAPI and analyzed by double immunoﬂuorescence microscopy using
the indicated primary antibody (GM130) and appropriate Alexa 568-conjugated secondary antibody. The images were collected with the same laser power and
settings and processed with Adobe Photoshop 7.0. Scale bar represents 25 µm. Individual examples of transfected cells are indicated by arrowheads.
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accompanied by a clear reduction in the protein level of all
lobe A subunits, whereas the protein level of lobe B subunits
was unchanged (Zolov and Lupashin 2005; Sun et al. 2007). In
contrast, Cog7p depletion was accompanied by reductions in
the protein level of lobe B subunits whereas the protein level of
lobe A subunits was unchanged (data not shown and Oka et al.
2005).
Compared with the normal Golgi ribbon observed in
control cells (Figure 1A and B and Supplementary data,
Figure S1B), Cog3p depletion resulted in a clear fragmenta-
tion of Golgi membranes with the appearance and accumu-
lation of vesicles (Figure 1A and B and Supplementary data,
Figure S1C). As shown by the colocalization study with two
different Golgi markers (GM130 and GPP130), both
GalT1-GFP and SiaT1-GFP were found distributed in these
CCD Golgi structures named CCD vesicles by Lupashin and
co-workers (Zolov and Lupashin 2005), demonstrating their
ability to be relocated into CCD vesicles under Cog3p
depletion (Supplementary data, Figure S1C).
Interestingly, a detailed analysis of siCog7-transfected cells
did not reveal an accumulation of these two Golgi enzymes in
CCD vesicles. Indeed, the steady-state level of both
GalT1-GFP and SiaT1-GFP was dramatically reduced in
Cog7p-depleted cells (Figure 1A and B), but without obvious
alterations of the overall structure morphology of the Golgi,
as indicated by the GM130 and the GPP130 stainings
(Figure 1A and B, and Supplementary data, Figure S1D). In
Cog7p-depleted cells, we noticed that the Golgi was less
fragmented, more compact and somewhat misshapen.
Similarly and independently from the GFP tag, a severe
alteration of its steady-state level was also observed for
endogenous B4GALT1 (Supplementary data, Figure S1A).
Thus, these results demonstrate that lobe B of the COG
complex is crucial for the localization and the steady-state
level of B4GALT1 and ST6GAL1. To further assess the stab-
ility of GalT1-GFP and SiaT1-GFP during Cog3p or Cog7p
depletion, western blot assays using a mAb speciﬁc for GFP
were performed (Figure 2B and D). No major decrease in both
GalT1-GFP and SiaT1-GFP was observed in siCog3-treated
cells. However, Cog7p depletion dramatically affected the
steady-state level of both GalT1-GFP and SiaT1-GFP
(Figure 2B and D). The same effect was observed on endogen-
ous B4GALT1 (Figure 2C). To exclude any potential effects of
siRNA-mediated Cog7p depletion on the mRNA level or stab-
ility of B4GALT1 and ST6GAL1, a QPCR-based approach
was performed. Compared with control cells, the mRNA
levels of B4GALT1 and ST6GAL1 were not signiﬁcantly
affected in Cog7p-depleted cells (Supplementary data,
Figure S2A and B). Accordingly, these results allowed us to
conclude that the observed alterations in the steady-state levels
of B4GALT1 or ST6GAL1 in siCog7-transfected cells are not
associated with any transcriptional regulation.
Altogether, our results strongly suggest that lobe B is
crucial for the steady-state level of both B4GALT1 and
ST6GAL1, whereas lobe A is necessary for maintaining the
normal Golgi structure.
Fig. 2. COG7 KD affects the steady-state levels of B4GALT1 and ST6GAL1. (A) Control, siCog3 and siCog7 total cell extracts from HeLa WT cells were
analyzed by immunoblotting using antibodies against the indicated COG subunits. (B and C) Control, siCog3 and siCog7 total cell extracts from HeLa cells
stably expressing GalT1-GFP were immunoblotted with anti-GFP and anti-B4GALT1 as indicated. (D) Control, siCog3 and siCog7 total cell extracts from HeLa
cells stably expressing SiaT1-GFP were analyzed by immunoblotting using anti-GFP antibody. Twenty micrograms of total cell extracts was loaded into each
lane, and anti-β-actin antibody was used as a loading control.
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Effects of proteasome and lysosome inhibitors on B4GALT1
and ST6GAL1 stabilities
To assess the mechanism(s) by which GalT1-GFP and
SiaT1-GFP could be degraded when cells were depleted for
Cog7p, proteasomal and lysosomal inhibitors were used. To
examine whether degradation of GalT1-GFP and SiaT1-GFP
was mediated by the proteasomal pathway, cells were treated
for 6 h with MG132, a speciﬁc proteasomal inhibitor. The
GalT1-GFP and/or SiaT1-GFP were detected both by western
blot assays and by immunoﬂuorescence microscopy. Although
Cog7p depletion was accompanied with a loss of GalT1-GFP
and SiaT1-GFP in untreated cells (Figure 2B and D), treat-
ment with MG132 signiﬁcantly increased both GalT1-GFP
and SiaT1-GFP protein levels by 62 ± 1.8 and 64 ± 3.1%,
respectively, compared with untreated control cells
(Figure 3B, lane 3, and C). Moreover, similar effects have
been shown for the endogenous B4GALT1 (Supplementary
data, Figure S2D), demonstrating that the effects of MG132
treatment on GalT1-GFP are not related to its overexpression.
The steady-state rescue for these two Golgi glycosyltrans-
ferases was conﬁrmed by immunoﬂuorescence microscopy, as
indicated by the predominant green staining in the perinuclear
region observed after MG132 treatment (Figure 4A and B).
Therefore, both GalT1-GFP and SiaT1-GFP were shown to
colocalize speciﬁcally with the Golgi marker giantin
(Figure 5A and B). Hence, this demonstrated that the MG132
treatment was not only able to rescue the steady-state levels of
GalT1-GFP and SiaT1-GFP but also their Golgi localization.
In contrast, by using the lysosomal inhibitors pepstatin A and
leupeptin in siCog7-treated cells, no effects either on the
Fig. 3. Effects of proteasome and lysosome inhibitors on the steady-state levels of B4GALT1 and ST6GAL1 in control and siCog7-transfected cells. HeLa cells
stably expressing GalT1-GFP (left) and SiaT1-GFP (right) were transfected with siCog7 at a concentration of 200 nM in the absence of fetal bovine serum. After
96 h, control (A) and siCog7-transfected (B) cells were treated with the indicated lysosomal and proteasomal inhibitors as described in the Materials and
Methods section. Twenty micrograms of whole-cell lysates was analyzed by immunoblotting using anti-GFP antibody, and anti-β-actin antibody was used as a
loading control. The abundance of the GalT1-GFP and the SiaT1-GFP in siCog7-transfected cells (lanes 2–5) treated with the indicated lysosomal and
proteasomal inhibitors was compared with untreated control cells (lane 1) in (C). Quantiﬁcations represent the mean values of three independent loadings of three
independent samples.
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GalT1-GFP and SiaT1-GFP levels (Figure 3B, lane 5) or on
their Golgi localization (Supplementary data, Figure S3A and
B) were observed. To exclude that the stabilization of
GalT1-GFP and SiaT1-GFP by the MG132 treatment was not
mediated by the Cog7p rescue, western blot assays with pAb
against Cog7p were performed in control and
siCog7-transfected cells treated with or without MG132. As
shown in supplemental data (Figure S2C), treatment with
MG132 had no effects on the protein level of Cog7p in
siCog7-transfected HeLa cells.
We then examined whether an alternative method to inhibit
lysosomal protease activity, by preventing the acidiﬁcation of
the endosomal/lysosomal system, could rescue the steady-state
levels of GalT1-GFP and SiaT1-GFP in siCog7-treated cells.
The acidiﬁcation was inhibited using the lysosomotropic weak
base chloroquine diphosphate and the carboxylic ionophore
monensin (see de Duve et al. 1974 for review).
SiCog7-transfected cells were treated with either chloroquine
or monensin, and the steady-state levels were analyzed by
western blot assays and by immunoﬂuorescence microscopy.
As observed in Figure 3B (lanes 2 and 4) and Supplementary
data, Figure S3, lysosomal inhibition by either chloroquine or
monensin had no effects on the rescue steady-state levels and
subcellular localization of GalT1-GFP and SiaT1-GFP.
Furthermore, the stability and/or localization of GalT1-GFP
and SiaT1-GFP in control cells after treatment with lysosome
inhibitors were checked, and as revealed by immunoﬂuores-
cence analysis, no major differences were observed compared
with untreated cells (Supplementary data, Figure S3A and B).
Taken together, these results allowed us to conclude that the
observed degradation of GalT1-GFP and SiaT1-GFP in
Cog7p-depleted cells was mediated by the proteasome
pathway.
Analysis of glycosylation defects in lobe A- and lobe
B-depleted cells
To highlight the Golgi N-glycosylation defects in lobe
A and lobe B depleted cells, various FITC-conjugated lectins
were used for ﬂow cytometry analysis. For this study,
the high-mannose structures speciﬁc lectin concanavalin
A (ConA), the Sambucus nigra agglutinin (SNA) that binds
to sialic acid terminally linked α(2–6) to galactose or
N-acetylgalactosamine residues, and the wheat germ aggluti-
nin (WGA) that binds terminal GlcNAc residues were used.
In order to validate lectin-binding speciﬁcity, complementary
competitive sugars that are known to block lectin binding
were used (Supplementary data, Figure S4). Figure 6 shows
histogram plots of control (Figure 6A), siCog3-transfected
(Figure 6B) and siCog7-transfected (Figure 6C) HeLa cells
incubated with FITC-labeled SNA and analyzed for SNA
binding. For each histogram, the ﬂuorescence peak corre-
sponding to SNA binding in the presence of 200 mM lactose
(nonspeciﬁc binding) is represented. Speciﬁc binding was cal-
culated as the difference between the mean ﬂuorescence inten-
sities of total and nonspeciﬁc peaks. Weak ﬂuorescence
intensity shifts for nonspeciﬁc SNA binding were observed
for siCog3- and siCog7-transfected cells in comparison to
control HeLa cells. These shifts were attributed to slight mor-
phological changes in cells, consecutive to the siRNA trans-
fection, as assessed by the FSC/SSC dot plot (data not
shown). As presented in Figure 6A, two distinct populations
of cells were observed in control HeLa cells. A very minor
population (left peak) was shown to overlay with
Fig. 4. Effects of the proteasome inhibitor MG132 on the subcellular
localization rescue of B4GALT1 and ST6GAL1 in control and
siCog7-transfected cells. HeLa cells stably expressing GalT1-GFP (A) and
SiaT1-GFP (B) were transfected with siCog7 at a concentration of 200 nM in
the absence of fetal bovine serum. After 96 h, cells were treated with MG132
as described in the Materials and Methods section, then ﬁxed and stained
with DAPI for analysis by immunoﬂuorescence microscopy. The images were
collected with the same laser power and settings and processed with Adobe
Photoshop 7.0. Scale bar represents 25 µm.
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neuraminidase-treated HeLa cells, which most likely corre-
sponds to cells presenting desialylated glycan structures. In
siCog7-transfected cells (Figure 6C), this population rep-
resented more than 42% of total cells and is characterized by
a loss of more than 97% of speciﬁc SNA binding.
siCog3-transfected cells (Figure 6B) showed an intermediate
ﬂuorescence pattern between control (Figure 6A) and
Cog7p-depleted cells (Figure 6C). Binding of ConA and
WGA lectins was also analyzed for control,
siCog3-transfected and siCog7-transfected cells (Figure 6D).
Owing to the weak ﬂuorescence intensity differences between
the total and the nonspeciﬁc peaks, which do not allow to dis-
criminate within the two populations (data not shown), the
results were expressed as percentages of speciﬁc lectin
binding to cells. In the calculation, speciﬁc lectin binding to
control cells, which corresponds to the difference between the
total and the nonspeciﬁc peaks, was considered as 100%. As
shown in Figure 6D, ConA binding did not evidence obvious
differences between control and siRNA-transfected cells. This
demonstrates that neither Cog3p nor Cog7p depletion affects
the early N-glycosylation steps. In contrast, a strong enhance-
ment for WGA-speciﬁc binding was observed in siCog3- and
Fig. 5. MG132 induced rescue on Golgi subcellular localization of GalT1-GFP and SiaT1-GFP. HeLa cells stably expressing GalT1-GFP (A) and SiaT1-GFP
(B) were transfected with siCog7 at a concentration of 200 nM in the absence of fetal bovine serum. After 96 h, cells were treated or not treated with MG132,
then ﬁxed and analyzed by double immunoﬂuorescence microscopy with the Golgi marker giantin. The images were collected with the same laser power and
settings and are processed with Adobe Photoshop Elements 7.0. Scale bar represents 25 µm.
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siCog7-transfected cells (+89 and +56%, respectively). These
observations clearly indicate moderate and severe abnormal-
ities in the terminal Golgi glycosylation for Cog3p- and
Cog7p-depleted cells, respectively.
COG sensitivity of a set of Golgi proteins
In order to determine whether the differential effects of lobe
A and lobe B of the COG complex on protein stability was
only observed for B4GALT1 and ST6GAL1, we analyzed the
effects of the depletion of the Cog3 or the Cog7 subunit, on a
subset of Golgi-associated proteins by western blot
(Figure 7). Proteins tested for a potential reduction or increase
in their steady-state levels in the Cog3- and/or Cog7-depleted
cells were αβSNAP, CASP, Exo70, GPP130, GS15, GS28 and
ZW10. Some are resident Golgi transmembrane proteins pre-
viously referred to GEARs: the golgin CASP, the Golgi phos-
phoprotein GPP130 and the SNARE protein GS15 (Oka et al.
2004). GPP130 is a glycoprotein of unknown function, whose
location in the Golgi is sensitive to changes in intraluminal
pH (Linstedt et al. 1997; Puri et al. 2002). The steady-state
level of both GPP130 and the exocytic intermediate protein
Exo70 was noticeably altered consecutively to the loss of
both lobe A and lobe B function. These proteins exhibited an
alteration of −20 and −11%, respectively, in their steady-state
level due to the loss of lobe A of the COG complex and of
−17 and −39%, respectively, after the disruption of lobe
B. Similarly, the protein GS15 was the only SNARE protein
to present a signiﬁcantly decreased expression (−31%) due to
the loss of the lobe B function and a slight alteration (−7%)
in its steady-state level after the disruption of the lobe A of
the COG complex. Inversely, some proteins appeared overex-
pressed in response to siCog3 or siCog7. The expression of
GS28 was indeed enhanced by 8 and 24% following the loss
of lobe A and lobe B function, respectively. Loss of the lobe
B of the COG complex was accompanied with a 15% increase
in the expression of αβSNAP, whereas CASP and ZW10 pro-
teins presented slight increases in their steady-state level fol-
lowing the loss of lobe A of the COG complex.
Discussion
Many studies have highlighted the crucial role of the hetero
octameric COG complex in establishing or maintaining the
Fig. 6. Analysis of glycosylation defects in control, siCog3-transfected and
siCog7-transfected cells by lectin staining and ﬂuorescence ﬂow cytometry.
HeLa WT cells were transfected with either siCog3 or siCog7 at a
concentration of 200 nM in the absence of fetal bovine serum. After 96 h,
cells were harvested, ﬁxed, permeabilized and incubated with
FITC-conjugated lectins for ﬂow cytometry analysis, as described in the
Materials and Methods section. Histogram plots of control (A),
siCog3-transfected (B) and siCog7-transfected (C) HeLa cells analyzed for
SNA binding and incubated with FITC-labeled SNA (total binding, black
tracing) are shown. For each histogram, the ﬂuorescence peak corresponding
to SNA binding in the presence of 200 mM lactose is represented
(nonspeciﬁc binding, grey ﬁll). Speciﬁc binding was calculated as the
difference between the mean ﬂuorescence intensities of total and
nonspeciﬁc-binding peaks. Desialylation was performed before the incubation
with lectins, using type V neuraminidase from Clostridium perfringens. One
representative experiment from a set of three independent experiments is
shown. In A, the SNA binding of neuraminidase-treated cells is also depicted
(dotted line). Binding of ConA and WGA lectins was also analyzed for
control (grey), siCog3-transfected (white) and siCog7-transfected (black) cells
in D. The results were expressed as the percentages of speciﬁc lectin binding
to cells. In the calculation, speciﬁc lectin binding to control cells, which
corresponds to the difference between the total and the nonspeciﬁc-binding
peaks, was considered as 100%. One representative experiment from a set of
three independent experiments is illustrated.
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normal structure and functions of the Golgi apparatus (Oka
et al. 2004; Zolov and Lupashin 2005; Shestakova et al.
2006). Over the past 5 years, mutations in COG complex sub-
units have been identiﬁed in CDG-II patients and all are
associated with defects in glycoconjugate synthesis, in the
stability and localization of resident Golgi proteins, in the
ultrastructure of the Golgi apparatus and in retrograde
intra-Golgi trafﬁcking (Wu et al. 2004; Spaapen et al. 2005;
Foulquier et al. 2006; Steet and Kornfeld 2006; Foulquier
et al. 2007; Kranz et al. 2007; Ng et al. 2007; Paesold-Burda
et al. 2009; Reynders et al. 2009). Strikingly, differential
effects in late Golgi glycosylation (sialylation and galactosyla-
tion) on total serum N-glycoproteins were observed depending
on the affected subunits (Foulquier et al. 2007; Kranz et al.
2007; Reynders et al. 2009). This led us to hypothesize that
individual COG subunits or subcomplexes may play distinct
roles in controlling stability and/or Golgi localization of late
Golgi glycosyltransferases. To address this point, a siRNA
strategy on Cog3 and Cog7 subunits, for a respective knock-
down of the lobe A and the lobe B of the COG complex in
HeLa cells stably expressing GFP-tagged B4GALT1 and
ST6GAL1, was used.
In the current study, we have characterized the conse-
quences of the loss of either lobe A or lobe B on the
steady-state levels and localization of the two major Golgi
glycosyltransferases involved in terminal N-linked glycosyla-
tion. We could establish that the acute depletion of the Cog3
subunit of the COG complex resulted in dramatic changes in
the Golgi structure, but did not have an effect on the
steady-state levels of GalT1-GFP and SiaT1-GFP. In contrast,
we demonstrated that the depletion of Cog7p severely altered
the stability of these two late Golgi glycosylation enzymes.
As already observed by Zolov and Lupashin (2005), Cog3p
depletion was associated with a clear fragmentation of Golgi
membranes leading to the appearance of CCD vesicles where
both GalT1-GFP and SiaT1-GFP were found to accumulate in
these structures. In contrast, immunoﬂuorescence analysis of
siCog7-transfected cells did not show an accumulation of
these two Golgi enzymes in CCD vesicles, but rather resulted
in a dramatic alteration of their steady-state levels. Similarly
and independently from the GFP tag, a complete instability
was also observed for the endogenous B4GALT1 under these
conditions. The steady-state levels of GalT1-GFP and
SiaT1-GFP under COG3 and COG7 KD were further assessed
by western blot analysis. As expected and in agreement with
the obtained immunoﬂuorescence data, no major decrease in
both enzymes was observed in Cog3p-depleted cells.
However, in siCog7-transfected cells, an 85% decrease in the
protein level was observed for both GalT1-GFP and
SiaT1-GFP. Given that Cog7p depletion affects the entire stab-
ility of the lobe B of the COG complex, our results clearly
point out that lobe B is crucial for the steady-state levels of
B4GALT1 and ST6GAL1. We then focused our study on the
mechanism of GalT1-GFP and SiaT1-GFP degradation under
Cog7p depletion. We demonstrated that lysosomal inhibition
by either pepstatin A/leupeptin, chloroquine or monensin had
no effects on the rescue levels of GalT1-GFP and SiaT1-GFP.
However, treatment with the proteasome inhibitor MG132
signiﬁcantly restored both GalT1-GFP and SiaT1-GFP
steady-state levels but also their Golgi localization. These
results therefore suggest that the degradation of GalT1-GFP
and SiaT1-GFP under siCog7 is likely the consequence of a
fast redistribution of these proteins into the ER, immediately
followed by a retrotranslocation into the cytosol and the pro-
teasomal degradation. Similar results have been observed in
ldlB and ldlC CHO cells by Oka et al. (2004) for a set of
integral membrane Golgi proteins called GEARs. In mutant
cells, GEARs proteins were found abnormally localized in the
ER and degraded by proteasomes. However, in contrast to the
work of Oka et al., we did not observe an increased amount
of the MG132-induced accumulation of GalT1-GFP and
SiaT1-GFP in the ER. Indeed, the observed Golgi rescue in
the GalT1-GFP and the SiaT1-GFP localization following
MG132 treatment suggests that lobe B KO most likely does
not affect efﬁcient ER exit and anterograde vesicular Golgi
trafﬁcking.
The molecular mechanisms by which the lobe B affects the
distribution of these two Golgi glycosyltransferases are
unknown but our results suggest that the lobe B would be
crucial in preventing these Golgi glycosyltransferases from
inappropriate retrograde trafﬁcking to the ER. Finally, the
analysis of glycosylation defects in both lobe A- and lobe
B-depleted cells was achieved by ﬂow cytometry analysis by
using FITC-conjugated lectins. We clearly demonstrated that
alterations in the late steps of N-linked oligosaccharide proces-
sing are independent of the affected lobes. However, deeper
abnormalities were associated with lobe B depletion.
To go further and discriminate with the functions of lobe A
and lobe B of the COG complex, we examined the effects of
efﬁcient knockdown of the Cog3 and Cog7 subunits, respect-
ively, on a subset of Golgi-associated proteins. Interestingly, the
subsequent loss of lobe A or lobe B function had different
effects on the steady-state level of some of the tested
secretory-pathway-related proteins suggesting that the observed
effect was not limited to B4GALT1 and ST6GAL1. The Golgi
phosphoprotein GPP130, the exocytic intermediate protein
Exo70 and the SNARE protein GS15 were the only proteins we
found whose steady-state levels were noticeably altered due to
the loss of either lobe of the COG complex. On the contrary, the
expression of the other COG sensitive proteins was either
enhanced or reduced following acute knockdown of either lobe
A or lobe B of the COG complex. Concerning proteins of the
intracellular trafﬁcking machinery, inactivation of the function
of the lobe B of the COG complex was mainly associated with
variations in the steady-state levels of the SNARE proteins
GS15 and GS28. Both GS15 and GS28 were shown to form a
SNARE complex with Syntaxin 5 with implications for
intra-Golgi transport (Xu et al. 2002) and in early/recycling
endosome to the TGN retrograde trafﬁcking steps (Tai et al.
2004). Genetic and physic interactions of the COG complex
with Golgi SNARE molecules and the vesicle coat complex
COPI in the retrograde intra-Golgi trafﬁcking were additionally
described in yeast (Ram et al. 2002; Suvorova et al. 2002). The
described interaction of several COG subunits with the yeast
SM (Sec1/Munc18) protein Sly1 further supported the hypoth-
esis that this complex might be involved not only in SNARE
stability, but also in promoting vesicular fusion by stabilizing
the ﬁnal SNARE complex (Shestakova et al. 2007).
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In conclusion, our results emphasize for the ﬁrst time an
independent and differential role of lobe A and lobe B COG
subcomplexes for the stability and localization of trans-Golgi
enzymes. Both lobes are clearly required for efﬁcient terminal
Golgi glycosylation, and the depletion of either lobe A or B
leads to moderate to severe Golgi glycosylation defects. In
addition, lobe A and lobe B differently affect the localization
and stability of two late Golgi glycosyltransferases B4GALT1
and ST6GAL1. Our results then suggest that lobe A KD
likely affects the Golgi glycosylation by leading to a misloca-
lization of trans-Golgi glycosyltransferases in CCD vesicles
then preventing the Golgi glycosyltransferases to be in contact
with the cargo molecules that need to be glycosylated. At the
opposite, the dramatic effects of lobe B KD on terminal Golgi
glycosylation result from the complete loss of B4GALT1 and
ST6GAL1. These results are in good agreement with the
different glycosylation abnormalities observed in the sera of
COG-deﬁcient CDG-II patients.
Materials and methods
Cell culture and other reagents
Cell culture reagents were purchased from Lonza (Levallois-
Perret, France). HeLa cells stably expressing GalT1-GFP and
SiaT1-GFP enzymes were grown in DMEM supplemented
with 10% fetal calf serum and 2.5 mM L-glutamine (DMEM/
FCS) at 37°C and 5% CO2 in a humidiﬁed chamber. The pro-
teasome and lysosome inhibitors monensin (2 µM, 2 h),
MG132 (8 µM, 6 h), chloroquine (10 µM, 24 h), leupeptin
(50 µM, 24 h) and pepstatin (1 µM, 24 h) were from
Sigma-Aldrich (St Louis, MO) and were investigated at the
respective concentrations and incubation times given in brack-
ets. Subconﬂuent monolayers were incubated in the DMEM/
FCS medium to which the agents were added immediately
before the experiment to the suitable ﬁnal concentrations,
whereas controls were incubated with the same volumes of
fresh medium and solvent.
Antibodies
Afﬁnity-puriﬁed or crude serum rabbit polyclonal antibodies
(pab) were used against the Cog3 and Cog7 subunits in
dilutions 1:1000 for western blotting. Pab against Cog3 and
B4GALT1 (1:250 for indirect immunoﬂuorescence and 1:750
for western blotting) were gifts from V. Lupashin (University
of Arkansas for Medical Sciences, Little Rock) and
E. G. Berger (University of Zürich, Zürich, Switzerland),
respectively. Mab anti-GM130 (1:100 for indirect immuno-
ﬂuorescence) and anti-GS15 (1:500 for western blotting) were
from BD Biosciences (Franklin Lanes, NJ). Mab anti-GFP
(1:1000 for western blotting) was from Sigma-Aldrich. Both
anti-giantin (1:1000 for indirect immunoﬂuorescence) and
anti-GPP130 (1:500 for western blotting) pab were from
Covance (Richmond, CA). Various antibodies used in
Figure 7 were gifts from different laboratories.
Immunoblotting
Twenty micrograms of proteins was analyzed by SDS–PAGE
and immunoblotted with the indicated antibodies at the concen-
trations described previously. Cells were rinsed twice with
ice-cold phosphate-buffered saline (PBS) and then lysed for 5
min on ice in cell lysis buffer (25 mM Tris–HCl, 150 mM
NaCl, pH 7.6, supplemented with 1% Triton X-100, 1% sodium
deoxycholate and 0.1% SDS). Proteins were quantiﬁed by using
the Micro BCA Protein Assay Kit (Thermo Fisher Scientiﬁc,
Brebieres, France). Signals were detected using the ECL Plus
Detection Kit (Amersham Biosciences, UK) according to the
manufacturer’s instructions. Signal detection was performed by
autoradiography and quantiﬁed with the GS800 Calibrated
Imaging Densitometer (Bio-Rad Laboratories, UK), using the
Quantity One software for image acquisition and analysis.
Immunoﬂuorescence staining
Cells were grown on glass coverslips, washed once with PBS
and ﬁxed by incubation for 30 min with 4%
Fig. 7. Analysis of the COG sensitivity of a set of Golgi proteins in siCog3- and siCog7-transfected cells. Total cell extracts from control, siCog3-transfected and
siCog7-transfected HeLa cells were analyzed by immunoblotting using antibodies to the indicated Golgi-related proteins. Twenty micrograms of total cell extracts
was each time loaded, and anti-β-actin antibody was used as a loading control. Quantiﬁcations represent the mean values of three independent loadings of three
independent samples for both COG3 and COG7 KD.
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paraformaldehyde in 0.1 M sodium phosphate buffer (pH 7.2)
at room temperature. The coverslips were rinsed three times
with PBS for 5 min. The ﬁxed cells were permeabilized with
PBS containing 0.5% Triton X-100 for 5 min and washed
three times with PBS. The ﬁxed cells were then incubated for
at least 60 min with a blocking solution containing 0.1%
Triton X-100 (Sigma-Aldrich), 1% BSA (Roche Applied
Science) and 5% normal goat serum (Invitrogen) in PBS.
After blocking, the cells were incubated overnight at 4°C with
primary antibodies diluted in the blocking solution as
described previously. The cells were then washed again three
times in PBS, followed by incubation with the Alexa 488- or
Alexa 568-conjugated secondary antibodies (1:500,
Invitrogen) for 1 h at room temperature in dark. Cells were
then post-stained with 500 ng mL−1 DAPI (Sigma-Aldrich)
for 5 min to detect cell nuclei, and washed three times with
PBS. Immunostaining was detected through an inverted Leica
SP5 spectral microscope (IRI CNRS USR 3078, Villeneuve
d’Ascq, France) with a 63× oil immersion lens at room temp-
erature. Data were therefore collected using the LAS 6000 AF
software and ﬁnally processed in Adobe Photoshop 7.0
(Adobe Systems, San Jose).
Lectin binding and ﬂow cytometry assay
Control, siCog3-transfected and siCog7-transfected cells were
harvested in 2 mM EDTA for 15 min at room temperature,
ﬁxed with 4% PFA in PBS on ice for 30 min, and then incu-
bated in 50 mM NH4Cl on ice for 15 min. After two washes
with PBS, cells were permeabilized with 0.3% saponin and
0.1% BSA for 15 min at 4°C. Cells were then washed once in
PBS and resuspended to ﬁnal concentration of 1 × 106 cells
mL−1 in PBS containing 0.1% BSA. All washing and incu-
bation steps were carried out in the BSA solution.
Desialylation was performed before the incubation with
lectins, using 50 mU of type V neuraminidase from
Clostridium perfringens (Sigma-Aldrich) in 50 mM sodium
acetate buffer, 0.9% NaCl, 0.1% CaCl2, 1% BSA, pH 5.0, for
3 h at 37°C. Twenty micrograms of FITC-labeled lectins from
stocks solutions of lectins of concentration 2 and 5 mg mL−1
was added to 50 µL cell suspension aliquots of 5 × 104 cells.
All lectins were purchased from Vector Laboratories
(Burlingame, CA). Final volumes were made up to 150 µL.
Incubations were carried out in the dark for 30 min with
occasional agitation. In addition, the degree of speciﬁcity of
lectin binding was determined by incubation with appropriate
monosaccharide inhibitors. These adequate competitive sugars
were preincubated with lectins for 1 h prior to addition of
cells. The FITC-labeled lectins and corresponding sugar
inhibitors were: the ConAwhich speciﬁcally binds to α-linked
Man residues or terminal Glc and is inhibited with 200 mM
α-methylmannoside; the SNA which binds to α2,6-linked
NeuAc residues and is inhibited with 200 mM Lac; and
ﬁnally, the WGAwhich binds to β1,4-linked GlcNAc residues
and is inhibited with 100 mM GlcNAc.
Flow cytometry analysis was performed on a Becton-
Dickinson FACSCalibur ﬂow cytometer (Le-Pont-De-Claix,
France). Immediately after incubation with lectins, cells were
resuspended in 500 µL of Isoton solution (Becton-Dickinson,
Le-Pont-De-Claix) and submitted to cytometry analysis. Each
analysis was performed on at least 10,000–20,000 cells gated on
the region of the HeLa cells population, based on light scatter
properties (forward versus side: FSC/SSC). Fluorescence inten-
sity data from the FL1 (green ﬂuorescence) channel were col-
lected and analyzed using the Cell Quest Pro software.
RNA interference experiment
Microsynth Laboratory (Balgach, Switzerland) manufactured
all siRNAs. Both siCog3 and the two Stealth siCog7 duplex
sequences have been published previously by the Lupashin
laboratory (Zolov and Lupashin 2005; Shestakova et al. 2006).
Duplexes were transfected at a ﬁnal concentration of 200 nM
by using Lipofectamine 2000 (Invitrogen) according to the
manufacturer’s instructions with slight modiﬁcations. Cells
were tranfected in OptiMEM medium, in the absence of fetal
bovine serum. Two cycles of siRNA were done to achieve
maximal knockdown, every 48 h. Cells were transfected with
corresponding siRNAs and collected for analysis 96 h later.
Real-time reverse transcriptase–PCR
Total RNA was isolated using the Nucleospin RNA II Kit
(Macherey Nagel, Hoerdt, France). The amount of extracted
RNA was quantiﬁed using a NanoDrop spectrophotometer
(Thermo Scientiﬁcs, Wilgminton, DE) and the purity of RNA
was checked by the ratio of the absorbance at 260 and 280
nm. Two micrograms of puriﬁed total RNA was then sub-
jected to reverse transcription with the First-Strand cDNA
Synthesis Kit (GE Healthcare), following the manufacturer’s
instructions. For PCRs, cDNAs obtained after reverse tran-
scription were diluted 1:5. PCRs were performed for the
B4GALT1 (GenBank NM_001497) and ST6GAL1 (GenBank
NM_003032) genes and for the house-keeping gene HPRT
(Hypoxanthine PhosphoRibosylTransferase, GenBank
NM_000194), which was used as an endogenous control for
normalization. PCR primers were designed using Primer 3
software (http://frodo.wi.mit.edu). All the primers were syn-
thesized by Eurogentec (Seraing, Belgium). PCR primers
used are the following: B4GALT1 (5′-GCAAAGCAGAACC
CAAATGT-3′ and 5′-GCAAAGCAGAACCCAAATGT-3′),
ST6GAL1 (5′-GGCATCAAGTTCAGTGCAGA-3′ and 5′-TG
CGTCATGATCATCGATTT-3′) and HPRT (5′-GCCAGACTT
TGTTGGATTTG-3′ and 5′-CTCTCATCTTAGGCTTTGTAT
TTTG-3′). PCRs (25 µL) were performed using 2X SYBR®
Green Universal QPCR Master Mix (Stratagene, Amsterdam,
The Netherlands) with 2 µL of a 1:5 cDNA dilution and 300
nM ﬁnal concentration of each primer. Data were analyzed
using the MX4000 PCR system software (Stratagene). To
quantify the results, we used the comparative threshold cycle
method described by Livak and Schmittgen (2001). Serial
dilutions were used to create standard curves for relative
quantiﬁcation, and glycosyltransferases transcripts were nor-
malized to HPRT expression.
Supplementary data
Supplementary data for this article are available online at http://
glycob.oxfordjournals.org/.
R Peanne et al.
874
Funding
This work was supported by grants from the Marie Curie
European Reintegration Grant and PEPS CNRS to F.F. This
work was also supported by the Centre National de la
Recherche Scientiﬁque (CNRS).
Conﬂict of interest
None declared.
Acknowledgements
We feel indebted to Dr. Eric Berger for his interest, contri-
bution, help and suggestions concerning this story. We
acknowledge the support of Dr. Wim Annaert for helpful
discussions.
Abbreviations
B4GALT1, β1,4-galactosyltransferase 1; CCD, COG complex-
dependent; CDG, congenital disorders of glycosylation; CHO,
Chinese hamster ovary; COG, conserved oligomeric Golgi;
ConA, concanavalin A; ER, endoplasmic reticulum; GFP,
green ﬂuorescent protein; MAB, monoclonal antibody; PAB,
polyclonal antibody; PBS, phosphate-buffered saline; QPCR,
quantitative polymerase chain reaction; SNA, Sambucus nigra
agglutinin; siRNA, small-interfering RNA; ST6GAL1,
α2,6-sialyltransferase 1; WGA, wheat germ agglutinin.
References
de Duve C, de Barsy T, Poole B, Trouet A, Tulkens P, Van Hoof F. 1974.
Commentary. Lysosomotropic agents. Biochem Pharmacol.
23:2495–2531.
Elsner M, Hashimoto H, Nilsson T. 2003. Cisternal maturation and vesicle
transport: Join the band wagon! Mol Membr Biol. 20:221–229.
Ferrari MC, Parini R, Di Rocco MD, Radetti G, Beck-Peccoz P, Persani L.
2001. Lectin analyses of glycoprotein hormones in patients with congenital
disorders of glycosylation. Eur J Endocrinol. 144:409–416.
Fotso P, Koryakina Y, Pavliv O, Tsiomenko AB, Lupashin VV. 2005. Cog1p
plays a central role in the organization of the yeast conserved oligomeric
Golgi complex. J Biol Chem. 280:27613–27623.
Foulquier F. 2009. COG defects, birth and rise! Biochim Biophys Acta.
1792:896–902.
Foulquier F, Ungar D, Reynders E, Zeevaert R, Mills P, García-Silva MT,
Briones P, Winchester B, Morelle W, Krieger M, et al. 2007. A new inborn
error of glycosylation due to a Cog8 deﬁciency reveals a critical role for
the Cog1-Cog8 interaction in COG complex formation. Hum Mol Genet.
16:717–730.
Foulquier F, Vasile E, Schollen E, Callewaert N, Raemaekers T, Quelhas D,
Jaeken J, Mills P, Winchester B, Krieger M, et al. 2006. Conserved oligo-
meric Golgi complex subunit 1 deﬁciency reveals a previously uncharacter-
ized congenital disorder of glycosylation type II. Proc Natl Acad Sci USA.
103:3764–3769.
Helenius A, Aebi M. 2004. Roles of N-linked glycans in the endoplasmic
reticulum. Annu Rev Biochem. 73:1019–1049.
Jaeken J, Vanderschueren-Lodeweyckx M, Casaer P, Snoeck L, Corbeel L,
Eggermont E, Eeckels R. 1980. Familial psychomotor retardation with
markedly ﬂuctuating serum prolactin, FSH, and GH levels, partial TBG
deﬁciency, increased arylsulfatase A and increase CSF protein: A new syn-
drome? Pediatr Res. 14:179.
Kornfeld R, Kornfeld S. 1985. Assembly of asparagine-linked oligosacchar-
ides. Annu Rev Biochem. 54:631–664.
Kranz C, Ng BG, Sun L, Sharma V, Eklund EA, Miura Y, Ungar D, Lupashin V,
Winkel RD, Cipollo JF, et al. 2007. COG8 deﬁciency causes new congenital
disorder of glycosylation type IIh. Hum Mol Genet. 16:731–741.
Linstedt AD, Mehta A, Suhan J, Reggio H, Hauri HP. 1997. Sequence and
overexpression of GPP130/GIMPc: evidence for saturable pH-sensitive tar-
geting of a type II early Golgi membrane protein. Mol Biol Cell.
8:1073–1087.
Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data
using real-time quantitative PCR and the 2DDCTmethod. Methods. 25:
402–408.
Lübbehusen J, Thiel C, Rind N, Ungar D, Prinsen BH, de Koning TJ,
van Hasselt PM, Körner C. 2010. Fatal outcome due to deﬁciency of
subunit 6 of the conserved oligomeric Golgi complex leading to a new
type of congenital disorders of glycosylation. Hum Mol Genet. 19:
3623–3633.
Ng BG, Kranz C, Hagebeuk EE, Duran M, Abeling NG, Wuyts B, Ungar D,
Lupashin V, Hartdorff CM, Poll-The BT, et al. 2007. Molecular and clinical
characterization of a Moroccan Cog7 deﬁcient patient. Mol Genet Metab.
91:201–204.
Oka T, Ungar D, Hughson FM, Krieger M. 2004. The COG and COPI com-
plexes interact to control the abundance of GEARs, a subset of Golgi inte-
gral membrane proteins. Mol Biol Cell. 15:2423–2435.
Oka T, Vasile E, Penman M, Novina CD, Dykxhoorn DM, Ungar D,
Hughson FM, Krieger M. 2005. Genetic analysis of the subunit organiz-
ation and function of the conserved oligomeric Golgi (COG) complex:
Studies of COG5- and COG7-deﬁcient mammalian cells. J Biol Chem.
280:32736–32745.
Paesold-Burda P, Maag C, Troxler H, Foulquier F, Kleinert P, Schnabel S,
Baumgartner M, Hennet T. 2009. Deﬁciency in COG5 causes a moderate form
of congenital disorders of glycosylation. HumMol Genet. 18:4350–4356.
Patterson GH, Hirschberg K, Polishchuk RS, Gerlich D, Phair RD,
Lippincott-Schwartz J. 2008. Transport through the Golgi apparatus by
rapid partitioning within a two-phase membrane system. Cell.
133:1055–1067.
Pelham HR, Rothman JE. 2000. The debate about transport in the Golgi—
two sides of the same coin? Cell. 102:713–719.
Puri S, Bachert C, Fimmel CJ, Linstedt AD. 2002. Cycling of early Golgi
proteins via the cell surface and endosomes upon lumenal pH disruption.
Trafﬁc. 3:641–653.
Ram RJ, Li B, Kaiser CA. 2002. Identiﬁcation of Sec36p, Sec37p, and
Sec38p: Components of yeast complex that contains Sec34p and Sec35p.
Mol Biol Cell. 13:1484–1500.
Reynders E, Foulquier F, Leão Teles E, Quelhas D, Morelle W, Rabouille C,
Annaert W, Matthijs G. 2009. Golgi function and dysfunction in the ﬁrst
COG4-deﬁcient CDG type II patient. Hum Mol Genet. 18:3244–3256.
Shestakova A, Suvorova E, Pavliv O, Khaidakova G, Lupashin V. 2007.
Interaction of the conserved oligomeric Golgi complex with t-SNARE
Syntaxin5a/Sed5 enhances intra-Golgi SNARE complex stability. J Cell
Biol. 179:1179–1192.
Shestakova A, Zolov S, Lupashin V. 2006. COG complex-mediated recycling
of Golgi glycosyltransferases is essential for normal protein glycosylation.
Trafﬁc. 7:191–204.
Spaapen LJ, Bakker JA, van der Meer SB, Sijstermans HJ, Steet RA, Wevers
RA, Jaeken J. 2005. Clinical and biochemical presentation of siblings with
COG-7 deﬁciency, a lethal multiple O- and N-glycosylation disorder.
J Inherit Metab Dis. 28:707–714.
Steet R, Kornfeld S. 2006. COG-7-deﬁcient human ﬁbroblasts exhibit altered
recycling of Golgi proteins. Mol Biol Cell. 17:2312–2321.
Sun Y, Shestakova A, Hunt L, Sehgal S, Lupashin V, Storrie B. 2007. Rab6
regulates both ZW10/RINT-1 and conserved oligomeric Golgi complex-
dependent Golgi trafﬁcking and homeostasis. Mol Biol Cell.
18:4129–4142.
Suvorova ES, Duden R, Lupashin VV. 2002. The Sec34/Sec35p complex, a
Ypt1p effector required for retrograde intra-Golgi trafﬁcking, interacts
with Golgi SNAREs and COPI vesicle coat proteins. J Cell Biol.
157:631–643.
Tai G, Lu L, Wang TL, Tang BL, Goud B, Johannes L, Hong W. 2004.
Participation of the syntaxin 5/Ykt6/GS28/GS15 SNARE complex in trans-
port from the early/recycling endosome to the trans-Golgi network. Mol
Biol Cell. 15:4011–4022.
Ungar D, Oka T, Brittle EE, Vasile E, Lupashin VV, Chatterton JE, Heuser JE,
Krieger M, Waters MG. 2002. Characterization of a mammalian
Golgi-localized protein complex, COG, that is required for normal Golgi
morphology and function. J Cell Biol. 157:405–415.
Ungar D, Oka T, Krieger M, Hughson FM. 2006. Retrograde transport on the
COG railway. Trends Cell Biol. 16:113–120.
COG and late Golgi glycosyltransferases
875
Van den Steen P, Rudd PM, Dwek RA, Opdenakker G. 1998. Concepts and
principles of O-linked glycosylation. Crit Rev Biochem Mol Biol.
33:151–208.
Wu X, Steet RA, Bohorov O, Bakker J, Newell J, Krieger M, Spaapen L,
Kornfeld S, Freeze HH. 2004. Mutation of the COG complex subunit gene
COG7 causes a lethal congenital disorder. Nat Med. 10:518–523.
Xu Y, Martin S, James DE, Hong W. 2002. GS15 forms a SNARE
complex with syntaxin 5, GS28, and Ykt6 and is implicated in
trafﬁc in the early cisternae of the Golgi apparatus. Mol Biol Cell.
13:3493–3507.
Zolov SN, Lupashin VV. 2005. Cog3p depletion blocks vesicle-mediated
Golgi retrograde trafﬁcking in HeLa cells. J Cell Biol. 168:747–759.
R Peanne et al.
876
